BOSTON - Compass Therapeutics, Inc. (NASDAQ: CMPX) shares gained 2.7% after the clinical-stage oncology company reported progress across its pipeline and provided a business update for 2024. While the ...
D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback